Previous 10 | Next 10 |
2023-06-05 17:18:34 ET Gainers: GitLab ( GTLB ) +19% . HealthEquity ( HQY ) +6% . Kezar Life Sciences ( KZR ) +5% . Ultragenyx Pharmaceutical ( RARE ) +4% . Vaxxinity ( VAXX ) +3% . Losers: Chijet Motor Compan...
Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-Founder and Chief Executive Officer, and Noreen R. Henig, M.D., Chief Medica...
2023-05-11 17:40:01 ET Kezar Life Sciences press release ( NASDAQ: KZR ): Q1 GAAP EPS of -$0.31. Cash, cash equivalents and marketable securities totaled $257.7 million as of March 31, 2023 For further details see: Kezar Life Sciences GAAP EPS of -$0.31
PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis on track to initiate in first half of 2023 KZR-261 dose escalation study continues to progress; the dose expansion study expected to initiate in second half of 2023 Cash, cash equivalents and marketable se...
(NewsDirect) Kalamazoo Resources Ltd (ASX:KZR) CEO Luke Reinehr tells Proactive the company is set to spin out its Australian lithium projects into a new ASX-listed exploration company, via a demerger and concurrent initial public offering (IPO) of Kali Metals Ltd (proposed ASX code: KM1). He...
2023-04-14 17:30:31 ET Gainers: Elevation Oncology ( ELEV ) +23% . Kezar Life Sciences ( KZR ) +16% . Vimeo ( VMEO ) +5% . Karyopharm Therapeutics ( KPTI ) +4% . LivaNova ( LIVN ) +3% . Losers: Silence Therapeutics&...
2023-03-28 17:27:17 ET Gainers: Arcturus Therapeutics ( ARCT ) +15% . lululemon athletica ( LULU ) +11% . Fate Therapeutics ( FATE ) +5% . Kezar Life Sciences ( KZR ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Losers: ...
2023-03-27 17:05:01 ET Gainers: Near Intelligence ( NIR ) +12% . Lyft ( LYFT ) +5% . Madrigal Pharmaceuticals ( MDGL ) +4% . Purple Innovation ( PRPL ) +4% . Pyxis Oncology ( PYXS ) +3% . Losers: Freightcar America ( RA...
2023-03-16 10:24:02 ET Kezar Life Sciences ( NASDAQ: KZR ) lost ~14% on Thursday morning after William Blair downgraded the clinical-stage biotech to Market Perform from Outperform following management comments at the company’s R&D event yesterday. The analyst...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, Mar...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...